AR121515A1 - Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisores - Google Patents
Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisoresInfo
- Publication number
- AR121515A1 AR121515A1 ARP210100576A ARP210100576A AR121515A1 AR 121515 A1 AR121515 A1 AR 121515A1 AR P210100576 A ARP210100576 A AR P210100576A AR P210100576 A ARP210100576 A AR P210100576A AR 121515 A1 AR121515 A1 AR 121515A1
- Authority
- AR
- Argentina
- Prior art keywords
- efficacy
- methods
- evaluate
- compositions
- transporter inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invención se refiere al campo de la farmacogenómica, el cual aplica uno o más biomarcadores genómicos y los dispositivos, reagentes, sistemas, equipos y métodos de diagnóstico relacionados para predecir respuestas individuales variadas, tales como, por ejemplo, eficacia o efecto adverso a los agentes terapéuticos, p. ej., inhibidores de ciertos transportadores de neurotransmisores, tales como liafensine.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062986603P | 2020-03-06 | 2020-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR121515A1 true AR121515A1 (es) | 2022-06-08 |
Family
ID=77613738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210100576A AR121515A1 (es) | 2020-03-06 | 2021-03-05 | Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisores |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230193388A1 (es) |
EP (1) | EP4106872A4 (es) |
JP (1) | JP2023515665A (es) |
KR (1) | KR20230005816A (es) |
CN (1) | CN115515680A (es) |
AR (1) | AR121515A1 (es) |
AU (1) | AU2021231683A1 (es) |
BR (1) | BR112022017770A2 (es) |
CA (1) | CA3174572A1 (es) |
IL (1) | IL296168A (es) |
MX (1) | MX2022010816A (es) |
TW (1) | TW202146660A (es) |
WO (1) | WO2021178166A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114848835B (zh) * | 2022-03-22 | 2023-08-25 | 暨南大学 | 塞来昔布的聚乙二醇修饰及连接叶酸基团的靶向药物分子及制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7901885B2 (en) * | 2006-05-09 | 2011-03-08 | Dsm Ip Assets B.V. | Genes and markers in type 2 diabetes and obesity |
WO2008065544A2 (en) * | 2006-09-11 | 2008-06-05 | Mcgill University | Genetic predictors of risk for type 2 diabetes mellitus |
US20110189663A1 (en) * | 2007-03-05 | 2011-08-04 | Cancer Care Ontario | Assessment of risk for colorectal cancer |
US20170029892A1 (en) * | 2009-05-29 | 2017-02-02 | Jay L. Lombard | Methods and compositions for the treatment of post-traumatic stress disorder |
US8355927B2 (en) * | 2010-11-05 | 2013-01-15 | Genomind, Llc | Neuropsychiatric test reports |
WO2012156515A1 (en) * | 2011-05-18 | 2012-11-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | Molecular analysis of acute myeloid leukemia |
US20170253928A1 (en) * | 2013-03-15 | 2017-09-07 | Pathway Genomics Corporation | Method and system to predict response to treatments for mental disorders |
US20140274764A1 (en) * | 2013-03-15 | 2014-09-18 | Pathway Genomics Corporation | Method and system to predict response to treatments for mental disorders |
ES2726650T3 (es) * | 2014-03-14 | 2019-10-08 | Caredx Inc | Métodos de monitorización de terapias inmunosupresoras en un receptor de trasplante |
-
2021
- 2021-02-23 MX MX2022010816A patent/MX2022010816A/es unknown
- 2021-02-23 EP EP21764344.4A patent/EP4106872A4/en active Pending
- 2021-02-23 IL IL296168A patent/IL296168A/en unknown
- 2021-02-23 CA CA3174572A patent/CA3174572A1/en active Pending
- 2021-02-23 BR BR112022017770A patent/BR112022017770A2/pt unknown
- 2021-02-23 CN CN202180031602.1A patent/CN115515680A/zh active Pending
- 2021-02-23 KR KR1020227034374A patent/KR20230005816A/ko unknown
- 2021-02-23 US US17/905,511 patent/US20230193388A1/en active Pending
- 2021-02-23 WO PCT/US2021/019265 patent/WO2021178166A1/en unknown
- 2021-02-23 JP JP2022552541A patent/JP2023515665A/ja active Pending
- 2021-02-23 AU AU2021231683A patent/AU2021231683A1/en active Pending
- 2021-03-05 TW TW110107927A patent/TW202146660A/zh unknown
- 2021-03-05 AR ARP210100576A patent/AR121515A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN115515680A (zh) | 2022-12-23 |
WO2021178166A1 (en) | 2021-09-10 |
BR112022017770A2 (pt) | 2022-11-29 |
TW202146660A (zh) | 2021-12-16 |
IL296168A (en) | 2022-11-01 |
EP4106872A1 (en) | 2022-12-28 |
US20230193388A1 (en) | 2023-06-22 |
AU2021231683A1 (en) | 2022-09-22 |
JP2023515665A (ja) | 2023-04-13 |
EP4106872A4 (en) | 2024-04-10 |
CA3174572A1 (en) | 2021-09-10 |
KR20230005816A (ko) | 2023-01-10 |
MX2022010816A (es) | 2022-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP22051489A (es) | Compuestos inhibidores de metaloenzimas | |
CO2019004630A2 (es) | Composiciones de células t con car anti-bcma | |
CL2021001686A1 (es) | Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos (divisional de solicitud n° 201800378) | |
UY37134A (es) | Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4 | |
UY35908A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
BR112018012914A2 (pt) | composto, método para tratar, prevenir ou melhorar um ou mais sintomas de câncer, método para tratar, prevenir ou melhorar um ou mais sintomas de uma doença inflamatória e composição farmacêutica | |
CO2019009373A2 (es) | Compuestos heterocíclicos útiles como inhibidores duales de atx/ca. | |
CL2020001546A1 (es) | Compuestos de 4-azaindol. | |
CL2017002237A1 (es) | Proteína de unión de il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias. | |
CR20120303A (es) | Tratamientos para trastornos gastrointestinales | |
BR112016026950A2 (pt) | composições de rnai para angiotensinogênio (agt) e métodos de uso das mesmas | |
BR112018002503A2 (pt) | comutador em cascata entre pluralidades de lnas | |
CL2017001292A1 (es) | 4-oxo-3,4-dihidro-1,2,3-benzotraizinas como moduladores de gpr139 | |
CO2022013827A2 (es) | Compuestos y métodos para modular el empalme | |
BR112019004123A2 (pt) | sistemas e métodos para atuar dispositivos hidraulicamente atuados | |
CR20160132A (es) | Composiciones y método para tratar condiciones asociadas con el complemento | |
BR112013017499A2 (pt) | combinação de sirosingopina e inibidores mitocondriais para o tratamento de câncer e imunossupressão | |
AR121515A1 (es) | Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisores | |
CO2022015926A2 (es) | Compuestos y métodos para modular el empalme | |
CO2019002909A2 (es) | Tratamientos de combinación que comprenden la administración de imidazopirazinonas | |
BR112022022409A2 (pt) | 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2 | |
BR112022005711A2 (pt) | Métodos e composições para tratar uma doença ou transtorno | |
ECSP11011486A (es) | Producción de hidrocarburos de isopreno mejorada que usa citanobacterias diseñadas geneticamente | |
BR112018009463A2 (pt) | ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia | |
BR112017019841A2 (pt) | técnica de análise de amostra de tecido |